The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity
Biomolecules · 2023
DOI: 10.3390/biom13071095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Daniel S Labach und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, Dental Sciences Building Room 3007, London,…. Hauptthemen laut MEDLINE: COVID-19, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, CoVaRR-Net Rapid Response Research Grant, Mitacs Accelerate.
Abstract (Originalsprache)
The COVID-19 pandemic has highlighted an urgent need to discover and test new drugs to treat patients. Metal-based drugs are known to interact with DNA and/or a variety of proteins such as enzymes and transcription factors, some of which have been shown to exhibit anticancer and antimicrobial effects. BOLD-100 (sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]dihydrate) is a novel ruthenium-based drug currently being evaluated in a Phase 1b/2a clinical trial for the treatment of advanced gastrointestinal cancer. Given that metal-based drugs are known to exhibit antimicrobial activities, we asked if BOLD-100 exhibits antiviral activity towards SARS-CoV-2. We demonstrated that BOLD-100 potently inhibits SARS-CoV-2 replication and cytopathic effects in vitro. An RNA sequencing analysis showed that BOLD-100 inhibits virus-induced transcriptional changes in infected cells. In addition, we showed that the antiviral activity of BOLD-100 is not specific for SARS-CoV-2, but also inhibits the replication of the evolutionarily divergent viruses Human Immunodeficiency Virus type 1 and Human Adenovirus type 5. This study identifies BOLD-100 as a potentially novel broad-acting antiviral drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, Dental Sciences Building Room 3007, London, ON N6A 5C1, Canada.
- Bold Therapeutics Inc., 422 Richards St, Suite 170, Vancouver, BC V6N 2Z4, Canada.
ORCID-Profile: Stephen D Barr
Förderung
- CIHR
- CoVaRR-Net Rapid Response Research Grant
- Mitacs Accelerate
- Bold Therapeutics Inc.
- National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP)
Zitieren
APA
Labach, D. S., Kohio, H. P., Tse, E. A., Paparisto, E., Friesen, N. J., Pankovich, J., Bazett, M., & Barr, S. D. (2023). The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity. Biomolecules. https://doi.org/10.3390/biom13071095
Vancouver
Labach DS, Kohio HP, Tse EA, Paparisto E, Friesen NJ, Pankovich J, et al. The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity. Biomolecules. 2023. doi:10.3390/biom13071095
BibTeX
@article{Labach2023,
author = {Labach, Daniel S and Kohio, Hinissan P and Tse, Edwin A and Paparisto, Ermela and Friesen, Nicole J and Pankovich, Jim and Bazett, Mark and Barr, Stephen D},
title = {The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity},
journal = {Biomolecules},
year = {2023},
doi = {10.3390/biom13071095}
}
EUVIMED